About US
Contact us
-
Forget a Roche merger; Novartis sell-offs could be imminent, analyst saysConsumer health, animal health, vaccines and diagnostics all on the table, with decision expected soon News flash from Basel: Yes, Novartis really is considering selling off a few of its units, in de2013/10/8
-
U.K.'s nod to J&J's Caelyx comes even as shortages expectedJanssen has warned docs to expect shortages starting next month The U.K. drug price watchdog today gave Johnson & Johnson's ($JNJ) Caelyx the distinction of being one of only two drugs it believe2013/9/30
-
FTC tells Mylan to sell 11 drugs to complete $1.6B Agila dealTheU.S. Federal Trade Commissionfavors Mylan's ($MYL) $1.6 billion buyout ofAgila Specialties, but is insisting the companies sell off 11 injectable drugs in markets where it believes the deal would h2013/9/30
-
Japan authorities digging deeper into Novartis' use of flawed Diovan studySometimes saying you're sorry just isn't enough. Swiss drugmaker Novartis ($NVS)has repeatedly apologized after learning that a company employee was affiliated with a study in Japan of blockbusterDiov2013/9/29
-
Boehringer's China expansion hits as probes leave market in turmoilGermany'sBoehringer Ingelheimtwo years ago started on a major addition to its operations inChinaas that rapidly expanding market looked like the promised land to many drugmakers. But the new facilitie2013/9/29
-
Merck gives up on unsuccessful Januvia combo drug JuvisyncMerck ($MRK) may have some dark clouds hanging overhead, but its multibillion-dollar diabetes franchise can usually be counted on for a bit of shine. As it announced cuts to its full-year sales foreca2013/9/27
-
There is no mark on the production equipment to show the production status and equipment status.German drugmaker sees opportunity in biosims, allergy fighters Merck KGaA is rejigging its pharmaceuticals management. Hoping some integration will amp up growth in the drugs business, the Darmstadt,2013/9/27
-
FDA names Kashmir-born official to head India operationsAltaf Ahmed Lal takes on a 'daunting challenge' The FDA has selected Altaf Ahmed Lal, an Indian-born Ph.D., to take over management of its expanding operations inIndia. Lal says collaboration with In2013/9/26
-
CFDA requires carrying out registration and disclosure of drug clinical trial informationIn order to strengthen the supervision and management of drug clinical trials, promote the transparency of drug clinical trial information, and protect the rights, benefits and safety of trial subject2013/9/26
-
GlaxoSmithKline's China sales set for 30% hit, analysts figureAs third-quarter earnings season nears, analysts are totting up the potential losses in China. And for GlaxoSmithKline ($GSK), at the heart of the pharma bribery scandal there, the damage to sales may2013/9/25